Arrowhead Pharmaceuticals Ratios and Metrics

Market cap in millions EUR. Fiscal year is October - September.

Millions EUR. Fiscal year is Oct - Sep.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2016 - 2020
Period Ending	Dec '25 Dec 1, 2025	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	2016 - 2020
Market Capitalization	6,571	4,064	2,159	2,721	3,568	5,616	Upgrade
Market Cap Growth	160.74%	88.24%	-20.66%	-23.72%	-36.47%	49.72%	Upgrade
Enterprise Value	6,445	3,904	2,184	2,644	3,246	5,191	Upgrade
Last Close Price	48.22	28.97	17.46	25.31	33.60	52.20	Upgrade
PS Ratio	9.30	5.75	678.12	11.96	14.38	47.07	Upgrade
PB Ratio	15.32	9.47	12.60	10.03	8.36	15.92	Upgrade
P/TBV Ratio	16.79	10.39	13.61	11.03	9.05	16.47	Upgrade
P/FCF Ratio	49.14	30.40	-	-	-	44.06	Upgrade
P/OCF Ratio	42.94	26.56	-	-	-	37.99	Upgrade
EV/Sales Ratio	9.03	5.52	686.02	11.63	13.09	43.51	Upgrade
EV/EBITDA Ratio	53.99	37.47	-	-	-	-	Upgrade
EV/EBIT Ratio	76.19	46.58	-	-	-	-	Upgrade
EV/FCF Ratio	48.20	29.20	-	-	-	40.72	Upgrade
Debt / Equity Ratio	1.46	1.46	4.46	1.34	0.20	0.06	Upgrade
Debt / EBITDA Ratio	5.29	5.29	-	-	-	-	Upgrade
Debt / FCF Ratio	4.68	4.68	-	-	-	0.17	Upgrade
Asset Turnover	0.66	0.66	0.00	0.33	0.35	0.22	Upgrade
Quick Ratio	4.73	4.73	6.57	3.75	2.67	2.58	Upgrade
Current Ratio	4.86	4.86	6.74	3.95	2.92	2.63	Upgrade
Return on Equity (ROE)	8.67%	8.67%	-254.98%	-59.33%	-42.68%	-32.36%	Upgrade
Return on Assets (ROA)	4.87%	4.87%	-39.43%	-17.58%	-15.91%	-15.11%	Upgrade
Return on Capital (ROIC)	5.39%	5.39%	-43.84%	-21.89%	-23.88%	-20.31%	Upgrade
Return on Capital Employed (ROCE)	8.30%	8.30%	-58.00%	-31.10%	-32.30%	-26.40%	Upgrade
Earnings Yield	-0.02%	-0.03%	-24.90%	-7.13%	-5.03%	-2.16%	Upgrade
FCF Yield	2.03%	3.29%	-25.10%	-11.48%	-5.40%	2.27%	Upgrade
Buyback Yield / Dilution	-11.67%	-11.67%	-12.21%	-1.26%	-1.62%	-3.00%	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.